LENSAR, Inc. (NASDAQ:LNSR) Sees Significant Drop in Short Interest

LENSAR, Inc. (NASDAQ:LNSR) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 49,800 shares, a decline of 22.6% from the October 15th total of 64,300 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average daily trading volume, of 31,200 shares, the days-to-cover ratio is currently 1.6 days.

LENSAR Trading Down 1.7 %

LENSAR stock traded down $0.12 during midday trading on Friday, hitting $7.08. The stock had a trading volume of 33,734 shares, compared to its average volume of 42,733. The stock has a market cap of $82.20 million, a P/E ratio of -4.85 and a beta of 0.59. LENSAR has a 12 month low of $2.10 and a 12 month high of $7.95. The business has a fifty day moving average price of $5.28 and a 200 day moving average price of $4.74.

Hedge Funds Weigh In On LENSAR

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Brandes Investment Partners LP boosted its stake in LENSAR by 12.8% in the second quarter. Brandes Investment Partners LP now owns 373,198 shares of the company’s stock valued at $1,644,000 after acquiring an additional 42,250 shares during the period. DCF Advisers LLC boosted its stake in LENSAR by 1.4% in the second quarter. DCF Advisers LLC now owns 241,484 shares of the company’s stock valued at $1,087,000 after acquiring an additional 3,250 shares during the period. Geode Capital Management LLC boosted its stake in LENSAR by 3.5% in the third quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock valued at $460,000 after acquiring an additional 3,423 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in LENSAR in the second quarter valued at approximately $93,000. 40.15% of the stock is currently owned by institutional investors and hedge funds.

About LENSAR

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.